Picard Medical Files 8-K Report
Ticker: PMI · Form: 8-K · Filed: Sep 10, 2025 · CIK: 2030617
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Picard Medical filed an 8-K, mostly boilerplate for now.
AI Summary
On September 9, 2025, Picard Medical, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events or financial figures detailed in the provided text. The report was filed as of September 10, 2025.
Why It Matters
This 8-K filing indicates Picard Medical, Inc. is providing updates or submitting required documentation to the SEC, though the specific nature of these events is not detailed in the excerpt.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific operational, financial, or strategic information that would indicate a change in risk.
Key Players & Entities
- Picard Medical, Inc. (company) — Registrant
- 0001829126-25-007290 (document_id) — Accession Number
- September 9, 2025 (date) — Date of earliest event reported
- September 10, 2025 (date) — Filing Date
- Tucson, AZ (location) — Principal executive offices
- 520-545-1234 (phone_number) — Registrant's telephone number
FAQ
What specific "Other Events" are being reported by Picard Medical, Inc. in this 8-K filing?
The provided excerpt of the 8-K filing does not detail the specific "Other Events" being reported.
What is the significance of the filing date and the date of the earliest event reported?
The filing date is September 10, 2025, and the date of the earliest event reported is September 9, 2025, indicating the report covers events that occurred on or before September 9th and was officially submitted on September 10th.
What is the principal business address of Picard Medical, Inc.?
The principal executive offices of Picard Medical, Inc. are located at 1992 E Silverlake, Tucson, AZ, 85713.
What is the SIC code for Picard Medical, Inc.?
The Standard Industrial Classification (SIC) code for Picard Medical, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Does this filing provide any financial statements or exhibits?
The filing lists "Financial Statements and Exhibits" as an item information category, but the excerpt does not contain the actual statements or exhibits.
Filing Stats: 626 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2025-09-10 16:15:35
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PMI The NYSE American, LL
- $4.00 — "Shares"), at a price to the public of $4.00 per share, generating gross proceeds of
- $17,000,000 — per share, generating gross proceeds of $17,000,000. The Company entered into an underwriti
- $2,550,000, b — roceeds to the Company of approximately $2,550,000, before deducting underwriting discounts,
- $19,550,000 — ed offering expenses, was approximately $19,550,000. On September 9, 2025, the Company iss
Filing Documents
- picardmedical_8k.htm (8-K) — 32KB
- picardmedical_ex99-1.htm (EX-99.1) — 12KB
- 0001829126-25-007290.txt ( ) — 209KB
- pmi-20250909.xsd (EX-101.SCH) — 3KB
- pmi-20250909_lab.xml (EX-101.LAB) — 33KB
- pmi-20250909_pre.xml (EX-101.PRE) — 22KB
- picardmedical_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. As previously reported on September 2, 2025, Picard Medical, Inc. (the "Company") completed its initial public offering (the "IPO") of 4,250,000 shares of Company's common stock, par value $0.0001 per share (the "Shares"), at a price to the public of $4.00 per share, generating gross proceeds of $17,000,000. The Company entered into an underwriting agreement with WestPark Capital, Inc., acting as the representative of the several underwriters (the "Representative"), in connection with the IPO, pursuant to which the Company granted the Representative an option, exercisable for 30 days, to purchase up to an additional 637,500 shares of common stock at the public offering price of $4.00 (the "Over-Allotment Option"). On September 9, 2025, the Company closed on the fully exercised Over-Allotment Option resulting in an additional gross proceeds to the Company of approximately $2,550,000, before deducting underwriting discounts, commissions and estimated offering expenses. After giving effect to the full exercise of the Over-Allotment Option, a total of 4,887,500 Shares have been issued and sold in the IPO and the gross proceeds from the IPO including the full exercise of the Over-Allotment Option, before deducting underwriting discounts, commissions and estimated offering expenses, was approximately $19,550,000. On September 9, 2025, the Company issued a press release announcing the exercise of the Over-Allotment Option by the Representative. A copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release, dated September 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Picard Medical, Inc. By: /s/ Patrick NJ Schnegelsberg Name: Patrick NJ Schnegelsberg Title: Chief Executive Officer Dated: September 10, 2025 2